Earnings Insights
AI-generated analysis of quarterly earnings, concall highlights, and financial performance across Indian listed companies.
How to use these insights
Each article is built from earnings call transcripts and structured rank signals. Start with the latest summary, then open the stock page for the full company view, the concall page for quarter-by-quarter commentary, and the rankings dashboard to compare peers.
Campus Activewear Q2 FY26 earnings call: Revenue & Margins | Arthneeti
Q2 FY26
Emphasis on expanding the premium sneaker segment, which is growing 100%+ year-on-year. Key concall takeaways from Campus Activewear Ltd's Q2 FY26 earnings…
5 Aug 2026
Campus Activewear Q4 FY25 earnings call: Revenue & Margins | Arthneeti
Q4 FY25
Expansion of sneaker segment (currently 8.5% contribution with 150% growth in FY25) and premium product mix will drive ASP and profitability. Key concall…
5 Aug 2026
Prudent Corporate Advisory Services Q4 FY25 earnings call: Revenue & Margins | Arthneeti
Q4 FY25
The company's total book and fresh business, including insurance premiums and PMS/AIF segments, are witnessing strong growth momentum (e.g., 80% growth in…
5 Aug 2026
Prudent Corporate Advisory Services Q3 FY25 earnings call: Revenue & Margins | Arthneeti
Q3 FY25
Profit growth resilient with standalone profit up 43% year-on-year in recent quarter. Key concall takeaways from Prudent Corporate Advisory Services Ltd's Q3…
5 Aug 2026
Rainbow Childrens Medicare Q1 FY26 earnings call: Revenue & Margins | Arthneeti
Q1 FY26
Around 50% of the total planned bed additions will be on an asset-light model. Key concall takeaways from Rainbow Childrens Medicare Ltd's Q1 FY26 earnings…
5 Aug 2026
Rainbow Childrens Medicare Q4 FY25 earnings call: Revenue & Margins | Arthneeti
Q4 FY25
Mature hospitals typically achieve 8-10% growth; new hospitals scale occupancy before increasing pricing and ARPOB. Key concall takeaways from Rainbow…
5 Aug 2026
Vaidya Sane Ayurved Laboratories Q4 FY25 earnings call: Revenue & Margins | Arthneeti
Q4 FY25
120 crores. Key concall takeaways from Vaidya Sane Ayurved Laboratories Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
5 Aug 2026
Gateway Distriparks Q3 FY26 earnings call: Revenue & Margins | Arthneeti
Q3 FY26
Capex plans are ongoing with INR100 to 150 crores per annum, mostly debt-financed (75%-80%) including build-to-suit expansions. Key concall takeaways from…
5 Aug 2026
Gateway Distriparks Q2 FY26 earnings call: Revenue & Margins | Arthneeti
Q2 FY26
Snowman Logistics plans INR100-150 crore annual capex for owning warehouses and fleet expansion, supporting volume and revenue growth. Key concall takeaways…
5 Aug 2026
Gateway Distriparks Q1 FY26 earnings call: Revenue & Margins | Arthneeti
Q1 FY26
Snowman intends to invest around INR100 crores in own and asset-light facilities, building 5-6 new warehouses in 3 years. Key concall takeaways from Gateway…
5 Aug 2026
Gateway Distriparks Q4 FY25 earnings call: Revenue & Margins | Arthneeti
Q4 FY25
100-150 crores per year for Snowman and Rs. Key concall takeaways from Gateway Distriparks Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
5 Aug 2026
Eureka Forbes Q2 FY26 earnings call: Revenue & Margins | Arthneeti
Q2 FY26
Profit after tax grew 32% YoY in Q2, indicating a positive profit trajectory moving forward. Key concall takeaways from Eureka Forbes's Q2 FY26 earnings call…
5 Aug 2026
Eureka Forbes Q4 FY25 earnings call: Revenue & Margins | Arthneeti
Q4 FY25
FY25 showed a revenue growth of 12% with six consecutive quarters of double-digit growth, led by high-teens product growth. Key concall takeaways from Eureka…
5 Aug 2026
Vedant Fashions Q2 FY26 earnings call: Revenue & Margins | Arthneeti
Q2 FY26
to high single-digit range, about 8% to 9%. Key concall takeaways from Vedant Fashions Ltd's Q2 FY26 earnings call — and how it ranks against sector peers.
5 Aug 2026
Vedant Fashions Q1 FY26 earnings call: Revenue & Margins | Arthneeti
Q1 FY26
Gross margins remain stable near 67%, with efforts focused on improving gross margin within categories despite product mix shifts. Key concall takeaways from…
5 Aug 2026
Vedant Fashions Q4 FY25 earnings call: Revenue & Margins | Arthneeti
Q4 FY25
Financial performance: Industry-leading gross margins (~67%), healthy EBITDA margins (~46%), and strong PAT margins (~28%) indicate robust profitability base…
5 Aug 2026
Vedant Fashions Q3 FY25 earnings call: Revenue & Margins | Arthneeti
Q3 FY25
Growth in Tier 2 and Tier 3 cities continues to outperform metros by ~5%. Key concall takeaways from Vedant Fashions Ltd's Q3 FY25 earnings call — and how it…
5 Aug 2026
Medplus Health Services Q2 FY26 earnings call: Revenue & Margins | Arthneeti
Q2 FY26
Diagnostics segment is currently a small part (<2%) and will expand only after crossing subscription thresholds. Key concall takeaways from Medplus Health…
5 Aug 2026
Medplus Health Services Q1 FY26 earnings call: Revenue & Margins | Arthneeti
Q1 FY26
Private label share is planned to grow steadily by around 0.5% per quarter, supporting margin expansion. Key concall takeaways from Medplus Health Services…
5 Aug 2026
Medplus Health Services Q3 FY25 earnings call: Revenue & Margins | Arthneeti
Q3 FY25
EBITDA margins around 5.1% considered sustainable, with slight upside possible but largely dependent on pace of store additions. Key concall takeaways from…
5 Aug 2026